Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Withdrawn 1Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 7INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Interventions

pembrolizumab 1HLX07 1Cetuximab 1CCT239065 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × CRC × Clear all
NCT07283367 2026-05-01

A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

Hansoh BioMedical R&D Company

Phase 1/2 Recruiting
502 enrolled

CRC

NCT07511972 2026-04-06

Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

NGM Biopharmaceuticals, Inc

Phase 2 Withdrawn

CRC

NCT04984369 2023-08-21

The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

Shanghai Henlius Biotech

Phase 2 Unknown
50 enrolled

CRC

NCT05239650 2022-05-03

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

Shanghai Henlius Biotech

Phase 2 Not yet recruiting
50 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡